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The number of people living with HIV globally is 33.4 
millions1. Systemic and oral lesions in HIV infection reflect the 
immune status of the patients and these lesions are important not 
only for the morbidity that they cause, but also for their diagnostic 
value in monitoring the immune status of the patient.  The 
occurrence of oral lesions indicate a great susceptibility for 
opportunistic infections and a great possibility for a rapid 
progression to AIDS2 , 3 ,4  
 
 The introduction of antiretroviral therapy (ART), especially 
combination therapy –has led to the reduction of opportunistic 
infections, mortality and morbidity in HIV infected patients.  Highly 
active antiretroviral therapy (HAART) is defined as an 
antiretroviral regimen containing a minimum of 3 drugs, nucleotide 
reverse transcriptase inhibitor (NRTI), protease inhibitor and non 
nucleotide reverse transcriptase inhibitor (NNRTI).5  
 
HPV infection is recognized as the most common sexually 
transmitted infection. The association between HPV and cervical 
cancer has been recognized6 .  In humans more than 70 types have 
been described (Zur Hausen ,  1996) .   Mucosal and genital HPV 
consisting of about 30  types ,are divided into low risk  (HPV 
6,11,42,43 and 44) and high risk  (HPV  16,18,31,33,35,45,51,52 
and 56),  according to their presence in  malignant lesions of the 
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cervix (Howy et al 1994)7. There are circumstantial evidence 
suggesting that high risk HPVs are involved in oral carcinogenesis8. 
 
Estimates of oral HPV prevalence is variable due to 
methodological or population differences and ranges from 9.2 – 
18.8%9. When HPV lesions are present in association with HIV 
infection, some patients experience a rather sudden occurrence and 
growth of new lesions in the mouth concurrently with deterioriation 
of the immune status. The oral warts caused by HPV are usually 1-
3mm in diameter, and may be located anywhere in the mouth, but 
most often on the labial or buccal mucosa or the gingiva10. 
 
Prevalence of  HPV associated oral condylomas have 
reportedly increased in HIV infected individuals since the 
introduction of HAART1 1  and oral warts due to HPV also have 
dramatically increased in the HAART era12.   Greenspan et al studied 
the effect of HAART on frequency of oral warts and found that  HIV 
infected patients on HAART were six times more likely to develop 
warts than patients not on HAART.  They also postulated that the 
functionally incomplete reconstitution of the immune system, 
observed in patients initiated on HAART could alter its  
effectiveness with regard to different potentially pathogenic 
microorgansisms and may probably lead to the development of oral 
warts in the context of an overall reduction of opportunistic 
infections1 3.     
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 Our initial studies reported absence of clinical oral warts in 
HIV patients on HAART1 4 ,3 Similarly in our earlier longitudinal  
study  in 2007, on oral lesions in HIV positive patients with and 
without HAART, HPV induced lesions were not encountered15.   
  
 It  has been stated that HPV frequently establishes a 
subclinical or latent infection in the oral cavity, which could serve 
as a reservoir for HPV transmission and future disease. It  has also 
been shown that saliva can be used to study the epidemiology of 
HPV infection of the oral cavity in HIV infected patients and by 
using saliva, oral HPV was detected equally in those on HAART and 
those not on HAART and those who did not have oral warts 
clinically. It  has also been documented that HPV infection was 
detected more frequently on those on effective HAART compared to 
those on clinically ineffective HAART11.  
 
 A cross sectional study was done at our centre (Ragas Dental 
college and Hospital,  Chennai) between  2009-2010  to determine 
HPV genome in the saliva of HIV seropositive  patients naive to 
HAART, and those who fulfilled the criteria for initiation of 
HAART.  L1 consensus primer which was common to all HPV was 
used in this study (by polymerase chain reaction). HPV was not 
detected in this study group16.   
 
 In the present study we followed the above patients 6 months 
after the commencement of HAART for detection of any HPV 
genome by PCR technique using L1 consensus primer to assess any 
latent infection by HPV. 
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AIM:  
To identify Human Papilloma Virus in Saliva of Human 
Immunodeficiency Virus (HIV) - Seropositive adults 6 months post 
HAART. 
 
OBJECTIVES: 
 To detect the presence of Human Papilloma Virus (HPV) in 
saliva of 
•  HIV seropositive adults on six months of  highly active 
anti retroviral therapy (HAART) 
•  HIV seronegative adults. 
 
HYPOTHESIS:  
 Initiation of HAART in HIV seropositive individuals does not 
influence the salivary HPV status.  
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STUDY DESIGN 
 A prospective study was done to ascertain oral HPV status in 
the saliva by using PCR to amplify the late gene L1 of HPV genome 
 
STUDY SUBJECTS: 
GROUP I : Ten HIV seropositive patients who were on HAART ≥  6 
months for whom HPV status was ascertained prior to initiation of 
HAART  
 
GROUP II : Ten HIV seronegative individuals. 
 
STUDY SETTING 
• Saliva samples were  collected from patients attending the out 
patient wing of YRG CARE, VHS, Chennai 
• Study  was conducted at Ragas Dental College and Hospital,  
Chennai 
 
STUDY PROCEDURE 
• Ethical clearance was obtained from the institutional review 
board of Ragas Dental College and from  YRGCARE 
• Informed consent was obtained from the patient 
• Demographic details of the patient were recorded 
• A thorough oral examination was done and findings were 
recorded in  prestructured case sheets 
• SAMPLE COLLECTION 
o  The patient was asked to sit  on a chair,  and after 
spitting any residual saliva present in his mouth, he was 
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asked to spit into a sterile container every minute for 
10 minutes to collect unstimulated whole saliva. 
(Journal of American academy of dermatology 2000, 
43: s18-26)  
o  5ml of unstimulated whole saliva was collected in the 
morning after breakfast (9:00 am – 11:00 am) from the 
study subjects (to avoid diurnal variation) 
o  Buccal mucosal scrapping was collected from 5 patients 
of group I selected randomly  
o  The sample was immediately transported to the research 
laboratory at Ragas dental college and hospital and 
stored at -700C until   DNA extraction 
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ARMAMENTARIUM 
1. For patient examination and sample collection 
•  Gloves and mouth masks 
•  Sterile mouth mirror and straight probe 
•  50ml sample collection containers 
•  Normal saline 
•  Wooden spatula 
2. For DNA extraction 
•  Microcentrifuge tubes 
•  Positive displacement pipettes  
•  DNA extraction kit 
•  Thermostat 
•  Cooling centrifuge 
3. DNA amplification 
•  Thermal cycler 
•  MY09/11 L1 consensus primer  
•  Housekeeping gene primers 
•  PCR master mix 
•  Positive control: HeLa cell l ine DNA 
4. Gel electrophoresis 
•  Agarose 
•  TAE (Tris Acetate EDTA) 
•  Ethidium bromide 
•  Horizontal electrophoresis unit 
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•  Microwave 
•  Gel Dock system 
 
DNA EXTRACTION 
 Saliva samples were taken from the deep freezer and kept for 
thawing till  they reached the room temperature.  
• 1500μ l of  saliva was taken in a 1.5ml micro centrifuge tube. 
• The tube was Centrifuged for 5 minutes at 13000rpm.1200μl  
of the supernatant was discarded from it.  
• 900μl  of Real Biotech Corporation (RBC) lysis buffer was 
added to it and mixed by inversion method. 
• The tube was incubated for 5 minutes at  room temperature. 
• It  was then centrifuged at 1300 rpm for 5 minutes and the 
supernatant was discarded. 
• 100 μl  RBC lysis buffer was added to resuspend the cell  
pellet.  
•  200μl  GB buffer was then added to the tube and mixed by 
vortex.  
• The mixture was incubated at room temperature for 10 
minutes until  the sample lysate became clear. During 
incubation, the tube was inverted every 3 minutes. 
• The required quantity of elution buffer (200μ l /  sample) was 
preheated in a 70°  C water bath (for DNA elution). 
• 200μl  of ethanol (96-100%) was added to the sample lysate 
and was mixed immediately by vortexing for 10 seconds. 
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•  GD (a tube with a sieve) column was placed in 2ml collecting 
tube. 
• Total mixture (including any precipitate) from the previous 
step was added to the GD column. 
• The cap of the column was closed and centrifuged at 
13000rpm. 
•  200μl  of GB buffer was added to it and centrifuged at 
6000rpm for 5 minutes. 
• 400 μl  of W1 buffer was added into the GD column and 
centrifuged at 13000 rpm for 30 seconds. 
• The flow-through was discarded and GD column was placed 
back in the 2ml collecting tube. 
• 600 μ l of wash buffer was added into the GD column. 
• It  was then centrifuged at 13000 rpm for 30 seconds, the 
flow-through was then discarded and the GD column was 
placed back in the 2ml collecting tube. 
• It  was then centrifuged at 13,000 rpm for 5 minutes to dry 
column matrix. 
• Dried GD column was then transferred into clean 1.5 ml 
micro-centrifuge tube. 
• 100 μ l of preheated elution buffer was added into the centre 
of column matrix. 
• It  was then allowed to stand at room temperature for 5 
minutes until  elution buffer is  absorbed by the matrix and 
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centrifuged at 13000 rpm for 30 seconds to elute purified 
DNA. 
• The extracted DNA was stored at -  4 ° C till  i t  was further 
used. 
 
DNA AMPLIFICATION USING PCR 
• The primers PC04 and GH20 were selected to amplify the β  
chain of haemoglobin to validate the PCR amplification of 
genomic DNA. 
• PC04 and GH20 primers yielded a product of 268 base pairs.  
• MY09/11 primers were used to amplify the L1 region of the 
HPV genome. 
• MY09/11 primers yielded a product of 450 base pairs.  The 
primer sequences were as follows: 
 
β  globin primer 
PC04 :   CAA CTT CAT CCA CGT TCA CC 
GH20 :   GAA GAG CCA AGG ACA GGT AC 
 
L1 consensus primers for HPV:  
MY 09 :   CGT CCM ARR GGA WAC TGA TC  
MY 11 :   GCM CAG GGW CAT AAY AAT GG 
 
• The primers,  DNA extracted from the sample, master mix, 
positive control and DEPC water were taken out from the 
deep freezer and kept for thawing. 
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• The laminar flow was cleaned with acetone and UV light was 
switched on for 30 minutes.  
• 50 μ l  reaction mixtures were prepared in the laminar flow unit  
using positive displacement pipettes as follows:  
 
 Positive control Sample 
Negative 
control 
Master mix 25 μ l 25 μ l 25 μ l 
MY 09 primer 1 μ l 1 μ l 1 μ l 
MY 11 primer 1 μ l 1 μ l 1 μ l 
PC 04 primer 1 μ l 1 μ l 1 μ l 
GH 20 primer 1 μ l 1 μ l 1 μ l 
DNA 
6 μl  of HeLa 
DNA 
6 μl  sample 
DNA 
6 μ l of DEPC 
water 
DEPC water 15 μ l 15 μ l 15 μ l 
 
Positive and negative controls were included in each PCR 
amplification cycle. The final 50μ l  reaction mixture was amplified 
in a thermal cycler.  The amplification programme was as follows: 
Number of cycles Temperature Time 
1 Initial denaturation 96 oc 5 minutes 
30 Denaturation 94 oc 
Annealing 63 oc 
Synthesis 72 oc 
1 minute 
1 minute 
1 minute 
1 Final extension 72 oc 5minutes 
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GEL ELECTROPHORESIS 
1.2% agarose gel was prepared using 1xTAE buffer and 
agarose powder. 0.72 grams of agarose powder was weighed and 
transfered into a clean conical flask, washed with deionised water.  
To this 60ml of 1xTAE buffer was added and it was heated in a 
microwave oven for one minute. The conical flask was taken out 
after every 20 seconds and swirled to mix. It  was then allowed to 
cool.  
 
Meanwhile, the gel electrophoresis tank, boat and comb were 
washed using deionised water. The ends of the gel boat were sealed 
using adhesive tape. 15μ l  Ethidium bromide was added to the 
agarose solution, it  was swirled well and poured into the gel boat 
having the gel comb. The agarose was allowed to cool and gel.  The 
gel comb was then removed slowly to leave behind wells in the gel.   
The adhesive tape was removed and the boat was placed in the tank. 
1xTAE was poured into the tank so as to immerse the gel 
completely. 
 
2μ l  of loading dye was mixed with 8μ l  of 100 base pairs DNA 
ladder and was loaded into the well in the gel.  8μ l  of sample,  
positive control and negative control were mixed with 2μ l of 
loading dye separately and loaded into the wells.  The gel tank was 
connected to the electrophoresis unit which delivered 100v electric 
current for 45 minutes. The electrophoresis unit was disconnected 
and the gel was taken out and placed on an UV illuminator and 
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visualised using Gel Dock system. The images of the gel was 
captured and stored. 
 
Positive control showed a beta globin band corresponding to 
268 base pairs and a HPV band corresponding to 450 base pairs of 
DNA ladder. The negative control did not have any band. All 
Samples showed a beta globin band whereas the HPV band was not 
present.  
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• Datas  were entered and   statistically analyzed  by using   
SPSST M   software  (Version 10.0.5) 
• Descriptive analysis was used to analyze the variables 
• Paired - t test was used for the variables CD4 and Hb count 
(to compare between pre HAART and post HAART 
• p value ≤  0.05 was considered to be statistically significant 
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Human Papilloma Virus Genome 
Stephen K Tyring (2000)17  reviewed the epidemiology, 
pathogenesis and host immune response of human papilloma virus 
and described the  HPV genome  as a closed ,double stranded 8 Kb 
DNA molecule that comprises early and late gene clustered in 
separate regions. Early gene codes for protein involved in viral 
DNA replication, transcription control and cellular transformation. 
Late gene encodes the major viral capsid protein (L1) and minor 
capsid protein (L2). Between these two regions is an upstream 
regulatory region (URR) also known as long control region. This 
non coding region contains promoters for E6 common to all HPVs 
but also one or more specific promoters in the URR.  
 
Lehtinen M and J Paavonen (2001)1 8  In their review on the 
efficacy of preventive human papilloma virus vaccination described 
that the DNA of Human Papilloma virus  consists of approximately 
8000 base pairs and comprises a long control region (LCR) and open 
reading frames (ORF) all  of which are transcribed at different 
stages of  the natural infection. Viral capsid consists of late L1 
(major) and L2 (minor) proteins but the latter is  not necessary for 
capsid assembly. Seven early ORFs (E1 to E8) specify regulatory 
proteins to participate in viral transcription (E2, E1), replication 
(E1, E2), interaction between viral and cellular proteins (E2-E7) 
and malignant transformation (E6, E7).  
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S Nair and MR Pillai (2005)7    in their review on relevance of 
Human Papilloma Virus disease mechanisms to oral and  cervical 
cancers ,  explained the genome of these viruses as a double stranded 
DNA molecule of about 8000bp. They also described the three 
genomic regions as a late region (L), an early region (E), and a long 
control region (LCR). The early gene E1 and E2  encodes for the 
protein involved in viral DNA replication and controls viral 
transcription. The products of gene E6 and E7    are essential in HPV 
induced cell immortalization and transformation and the late gene 
L1  and L2  encodes for the viral capsid protein.   
 
HPV in normal oral and cervical mucosa  
Badaracco G, Venuti A, Di Lonardo et al  (1998)1 9  in their study, 
analysed cervical smears and oral swabs from 29 women. HPV-DNA 
was detected in 34.5% cervical smears and 37.9% of oral swabs. 
HPV-16 was present in 53.8% and was the most prevalent genotype 
followed by HPV-6, which was present in 34.6% of the positive 
samples. Other types were rarely detected. Concurrent genital and 
oral HPV infection was seen in 5 patients (17.24%). 
 
Kurose K, Terai M, Soedarsono N and Rabello D (2004)2 0    
investigated the incidence of HPV infection in normal oral mucosa.  
They also followed the HPV-positive participants of this cohort 
study approximately 2.5 years after the first sample collection. Of 
the 662 samples analyzed, HPV was detected only in 0.6% of 
samples, suggesting that oral  HPV infection is uncommon. In the 
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follow-up survey, the HPV71 and HPV12-positive participants again 
tested positive, while HPV DNA was not detected in the HPV16 and 
HPV53-positive participants. 
 
Rojas M, Schlecht N and Nucci-Sack A (2007)2 1  et al  examined 
the prevalence of cervical,  anal and oral HPV in sexually active 
adolescents. They observed that infection with low-risk HPV types 
most associated with anogenital warts and condylomas was 40.6% in 
cervical,  30.4% in anal and 7.5% in oral mucosa. In addition 
infection with oncogenic HPV types was found to be as high as 
40.6% in cervical,  32.6% in anal,  and 4.3% in oral mucosa. 
 
Castro T, Filho I,  Nascimento V and Xavier S (2009)2 2  
investigated the presence of HPV DNA in the oral and genital 
mucosa of women with HPV genital infection, using the PCR .  Swabs 
were obtained from the oral and genital mucosa of 30 women with 
histopathologically confirmed HPV genital infection. HPV DNA was 
not detected in any oral swabs, while in the genital tract,  HPV was 
detected in 17 (57%) of the 30 patients.  They suggested that genital 
HPV does not seem to be a predisposing factor for the oral 
infection. 
 
HPV in normal, premalignant and malignant oral lesions 
Schwartz S, Daling J, Doody D et al  (1998)23  conducted a case-
control study to determine if  oral-cancer risk is related to HPV 
infection. HPV DNA was detected in 26% of tumours using PCR. 
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16.5 % of tumours contained HPV16 DNA. The Odds Ratio for HPV 
type 16 seropositivity was 2.3 for all  oral SCCs and 6.8 for oral 
SCCs containing HPV type 16 DNA. Their findings suggested that 
HPV16 infection may contribute to the development of a small 
proportion of OSCC. 
 
Elamin F, Steingrimsdottir H, Warnakulasuriya S et al  (1998)24  
evaluated the role of HPV in oral neoplasms using nested PCR. HPV 
16 and HPV 18 were the only types detected in all  tumors by HPV 
typing. HPV DNA was detected in 33% of premalignant lesions 
suggesting a possible role of HPV in oral epithelial dysplasia. 
 
Bouda M, Gorgoulis V, Kastrinakis G et al  (2000)2 5  examined 
HPV infection in oral hyperplasia, dysplasia and SCC as well as in 
normal mucosal specimens. HPV DNA was detected in 91% of 
pathological samples but not in normal specimens. Of the HPV DNA 
positive samples, 98% were infected with high-risk type,  whereas 
only 2% were infected with low-risk type of HPV. These findings 
suggest that high-risk HPV types are involved in oral 
carcinogenesis. 
 
Jimenez C, Correnti M, Salma N et al  (2000)26  investigated the 
presence of HPV infection in clinically normal and benign oral 
epithelial lesions. Biopsy specimens of 40 patients with benign 
epithelial  lesions and 20 patients with clinically normal mucosa 
were subjected to PCR analysis using MY09/11 primers. Viral DNA 
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was detected in 59% of oral benign lesions and 10% of biopsy 
specimens of normal mucosa. 
 
Ha P, Pai S, Westra W et al  (2002)  27  evaluated the role of HPV 16 
in the progression of oral head and neck cancer. They quantified the 
HPV 16 DNA in pre-malignant and malignant lesions using 
quantitative PCR. HPV DNA was detected in 0.98% of 102 
premalignant lesions and 2.9% of invasive oral cancers. 14 of the 18 
invasive tumors, previously found to be HPV positive by methods 
other than PCR, were positive by quantitative PCR. This suggested 
that HPV 16 may not play a major role in malignant progression of 
premalignant lesions. 
 
Sugiyama M, Bawal U, Dohmen T et al  (2003)28  studied the 
association between HPV and oral carcinogenesis.  They analysed 
specimens of normal mucosa, epithelial dysplasia and OSCC and 
OSCC cell lines, using PCR. HPV16 DNA was detected in 61% of 
epithelial dysplasia specimens, 36% of normal and 35% of OSCC 
tissues. HPV18 DNA was not detected in any of these cases, 
suggesting that HPV16 may be correlated with an early stage of oral 
carcinogenesis.  They suggested that even if HPV16 plays a role, i t  
just could be an initiator of proliferation and not a requisite for 
maintenance and progression of malignant stage. HPV cannot 
replicate in proliferating cultured cells that do not undergo 
differentiation and hence HPV DNA may be lost in later stages. 
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Patrick K and Califano J (2004)  29  reviewed the role of HPV in 
oral carcinogenesis. They stated that although epidemiological and 
molecular data provides evidence of high-risk HPV presence in oral 
pre-malignant and malignant lesions, it  is unlikely in most cases. 
HPV may be a contributing factor in subset of oral malignancies,  
but is  not a necessity in all cases as in cervical cancer. 
 
HPV in HIV sero positive patients 
Cappiello G, Garbuglia A, Salvi L et al  (1997)3 0  assessed the 
association between different HPV genotypes, HIV infection and 
cervical squamous intra-epithelial lesions (SIL) in 236 HIV 
seropositive women. The prevalence of HPV 16 and 18  was similar 
among both HIV-positive and HIV-negative women. HIV positive 
women showed a wider spectrum of HPV genotypes. 
 
Palefsky J, Holly E, Ralston M and Jay N (1998)3 1   studied the 
presence of anal HPV infection in 346 HIV positive and 262 HIV 
negative homosexual and bisexual men and detected anal HPV DNA 
in 93% of HIV-positive and 61% of HIV-negative men by 
polymerase chain reaction. HPV-16 was the most common type of 
HPV in both the groups. They also observed that lower CD4+ cell 
levels were associated with higher levels of oncogenic HPV types.   
 
Piketty C, Darragh M, Da Costa M et al  (2003)32  conducted a 
cross-sectional study to assess the prevalence of anal HPV in HIV 
positive men.  46% of the 50 HIV positive heterosexual injection 
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drug users and 85% of the HIV positive men who have sex with men 
had anal HPV infection. They concluded that anal HPV infection 
may be acquired in the absence of anal intercourse in HIV-positive 
men.  
 
Pinto A, Baggio H and Guedes G (2005)33  described the common 
sexually transmitted viral diseases. These included HIV, genital  
warts,  intra-epithelial lesions, genital squamous cell carcinomas and 
herpes simplex virus (HSV) infection. Women infected with HIV 
were found to be at a greater risk of being co-infected with HPV 
and are more prone to progression to persistence of HPV lesion. 
 
Shetty K, Chattopadhyay A and Leigh (2005)34  investigated and 
described the HPV types present in oral warts of HIV positive 
patients. DNA extracted from the 12 biopsy samples of patients who 
had a clinicopathologic diagnosis of oral warts,  were subject to 
multiplex PCR assay. HPV was detected in 11 of the 12 orals warts. 
HPV 32 and HPV 7 were the only HPV types detected. HPV-32 was 
present in all  subjects, whereas only one subject had a co-infection 
of HPV 32 and HPV 7. 
 
Sirera G, Videla S, Pinol N et al  (2006)3 5  evaluated the prevalence 
of HPV in the anus, penis and mouth of men who have sex with men 
(MSM) and hetero-sexual men. PCR was used for assessing the 
prevalence of HPV DNA. A high HPV prevalence of 78%, 36% and 
30% were noted in the anus, penis and mouth of HIV positive men 
22 
 
respectively.  The findings support the suggestion that presence of 
HPV infection should be determined in any HIV infected male 
patient.   
 
Palefsky J (2006)36  in his review said that  HIV-positive men and 
women are at an increased risk of anogenital and oral HPV 
infection. The risks for HPV-associated high-grade intra-epithelial  
neoplasia (IN) and cancer are also high. The prevalence of oral,  
anal,  and cervical HPV infection in HIV-positive individuals 
compared with HIV-negative individuals increases with 
progressively lower CD4+ levels.  Immune suppression plays a more 
prominent role in the earlier stages of HPV-associated disease.  
 
Fakhry C, D’Souza G, Sugar E et al  (2006)3 7  compared the 
prevalence and type distribution of oral and cervical HPV infection 
in HIV positive women. They detected HPV DNA in oral rinse and 
vaginal lavage samples. In HIV positive and negative women, the 
oral HPV infection was 25.2% and 9% and cervical HPV infection 
was 76.9% and 44.9% respectively. One-third of HPV types detected 
in the cervix were not detected in the oral cavity of the same 
women. Most women with an oral HPV infection also had a cervical 
infection. This suggests that oral cavity is a significant reservoir for 
HPV, which may not be entirely independent of as cervical 
reservoir. 
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Richter K, van Rensburg E, van Heerden W and Boy S (2008)3 8   
harvested oral epithelium from buccal mucosa and lateral borders of 
the tongue and cervical samples from the endocervical area of 30 
HIV infected women. Oral HPV was detected in 20% of the patients 
whereas genital HPV was found in 96.7% of the women, of whom 
only 14 had cytological abnormalities on Papanicolau smear. 
Women with CD4 counts less than 300 cells per ml had a significant 
risk of cervical HPV infection. Though HPV was detected in the 
oral cavity, only a limited correlation between oral and cervical 
HPV types was found. 
 
Singh D K, Anastos K and Hoover D R (2009)3 9  analysed  cytologic 
and HPV data available for 647 HIV-positive women and 188 HIV-
negative women in Ruwanda. They collected cervicovaginal lavage 
specimens and tested them for 40 HPV types by a PCR assay. They 
found that the prevalence of HPV was higher in HIV-positive 
women than in HIV-negative women in all  age groups. Among HIV-
infected women, 69% were positive for one HPV type, 46% for a 
carcinogenic HPV type, and 10% for HPV-16. HPV prevalence was 
the highest in the HIV-positive women aged 25–34 years (75%) and 
then declined with age to 37.5% in those >55 years old. A higher 
prevalence of HPV and carcinogenic HPV were associated with 
lower CD4+ cell counts and increasing cytologic severity among 
HIV-positive women. 
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Baumgarth N, Szubin R, Dolganov G, et al  (2004)  40  studied the 
expression of 166 genes in epithelial and sub-epithelial 
compartments of normal mucosa from HIV-infected and non-
infected patients and of HPV32-induced oral warts from HIV 
infected patients.  Changes in oral warts were strongly tissue 
substructure-specific. They suggested that HPV 32 establish 
infection by selectively enhancing epithelial cell growth and 
differentiation in the stratum spinosum and to evade the immune 
system by actively suppressing inflammatory responses in adjacent 
underlying tissues. 
 
 
Oral lesions in HIV infection 
Greenspan D and Greenspan S (1996) 2  reviewed the HIV related 
oral lesions most commonly encountered. Of these OC is the most 
common lesion. HIV related oral diseases may be grouped into 
lesions of fungal origin, lesions of bacterial origin, viral origin, 
auto immune and neoplastic conditions. 
 
Rangananthan K, Reddy B V R, Kumarasamy N et al (2000)1 4   
studied the prevalence of oral lesions in 300 HIV patients of south-
India. Oral lesions were seen in 72% of the patients. Gingivitis 
(47%) was the most common oral lesions followed by pseudo 
membranous candidiasis (PC) (33%), oral mucosal pigmentation 
(23%) and erythematous candidasis (EC) (14%). Other lesions that 
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were seen included periodontitis,  angular cheilitis,  oral ulcers, oral 
hairy leukoplakia (OHL) and oral sub mucous fibrosis. 
 
Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J  et al  
(2003)41  studied the prevalence of oral lesions in 1000 HIV patients  
over a period of 12 years stratified into 4 periods (2 were before the 
introduction of HAART and the last 2 were during more established 
use of HAART). OC (31.6%) and OHL (22.6%) were the most 
common lesions whereas oral KS, HIV associated periodontal 
disease and oral non-Hodgkin’s lymphoma was less frequent.  During 
the course of the 4 study periods, the oral lesions decreased 
systematically. Except kaposi sarcoma (KS), all  oral lesions 
strongly associated with HIV showed a significant decrease during 
the study period. There was no variation in the occurrence of 
salivary gland disease or HPV associated oral lesions. The patients 
with oral lesions which are strongly associated with HIV had lower 
median CD4+ cell counts. The decrease in oral disease was 
attributed to the use of prophylactic drugs and introduction of 
HAART. 
 
Ranganathan K, Umadevi K, Saraswathi T R et al  (2004)3  studied 
the oral lesions and gender differences in a large cohort of 1000 
HIV patients. Gingivitis (72.3%) was the most common oral lesion. 
Other oral lesions included periodontitis (33.2%), oral pigmentation 
(26.3%), OC (23.8%), angular cheilitis (7.9%), oral ulcers (3.3%), 
OHL (2.1%), leukoplakia (1.5%) and oral submucous fibrosis 
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(0.9%). The prevalence of oral lesions was more in males (88%) 
than females (82%). This difference in the occurrences was 
statistically significant. 
 
Leigh J, Kishore S and Fidel P (2004)42  reviewed the oral 
opportunistic infections and the role of mucosal immune function in 
HIV-positive individuals. They found that both systemic and local 
immunity were important for protection against oropharyngeal 
candidiasis.  Recent investigations into the host responses associated 
with OHL and oral warts did not show any evidence of systemic or 
mucosal immune responsiveness. 
 
Inés María Bravo María Correnti,  Laura Escalona et al (2005)4  
studied the prevalence of oral lesions in HIV patients related to 
CD4 cell count and viral load in a Venezuelan population. They 
evaluated 75 HIV seropositive adult patients and found that 85% of 
patients showed associated oral lesions .  oral candidasis constituted  
the most common lesion (61%) followed by oral hairy leukoplakia 
(34%), melanic hyper pigmentation (38%), papilloma (13%), lineal 
gingival erythema, apthous stomatitis (5%), Kaposi sarcoma (5%) 
and concluded that  high viral load was strongly associated with the 
occurrence of oral lesions independent of CD4 cell count. 
 
Maeve M. Coogan John Greenspan and Stephen J. Challacombe 
(2005) 4 3  discussed the importance of oral lesions as indicators of 
infection with HIV and as a predictor of progression of HIV disease 
27 
 
to acquired immune deficiency syndrome (AIDS). They described 
that oral manifestations are among the earliest and most important 
indicators of infection with HIV. Seven cardinal lesions, oral 
candidiasis,  oral hairy leukoplakia, Kaposi sarcoma, linear gingival 
erythema, necrotizing ulcerative gingivitis,  necrotizing ulcerative 
periodontitis and non hodgkins lymphoma were explained as 
strongly associated with HIV infection and have been identified 
internationally.  
 
Ranganathan K and Hemalatha R (2006)44  reviewed the literature 
on oral lesions affecting the HIV positive patients in developing 
countries. OC was the most common opportunistic infection in all 
continents. KS was limited to patients from Africa and Latin 
America. Salivary gland disease was more common in paediatric 
HIV subjects.  A high prevalence of gingivitis and periodontitis were 
reported from India and Africa. Considerable regional prevalence of 
oral manifestations were highlighted. 
 
Sharma G, KM Pai, S Suhas et al (2006)45  assessed the prevalence 
of HIV related oral lesions in South India. They concluded that oral 
hairy leukoplakia showed a positive relationship with patients  
younger than 35 years. Oral candidasis can act as a marker of 
immune suppression 
 
Alan Grupioni Lourenco, Luiz Tadeu Moraes e (2008)4 6  studied 
the prevalence of oral lesions in 340 HIV infected individuals of 
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Brazil.  The oral lesions encountered in their study were oral 
candidiasis (17.7%), angular chelitis (13.9%), hairy leukoplakia 
(11.8%) and oral ulcers (2.1%). They concluded that oral lesions 
inversely correlates with CD4 count and directly correlates with 
HIV viral load and suggested that oral lesions could be used as an 
alternative clinical marker for poor immune condition in HIV 
infected individuals. 
 
ORAL LESION IN HIV POST HAART 
Andrea M, Frank P, Frank B and Peter R (2000)  47compared the 
prevalence of oral lesions in HIV-seropositive before and after the 
initiation of HAART. One hundred and three HIV serpositive 
patients (88 men and 15 women) who were on combination therapy 
for at least four weeks at the t ime of study were included . They re-
evaluated the patients twice in an interval of six months each and 
the most frequent lesions were OHL and OC. The prevalence of oral 
lesions after the onset of HAART decreased significantly in their 
study but in four patients the immunological effects of therapy did 
not provide sufficient protection against HPV induced lesions. 
 
Eyeson J D, Flowers M T, Cooper D J et al  (2002)  4 8  determined 
the prevalence of oral lesions in HIV positive patient,  
predominantly on HAART. 49% of the patients had no detectable 
oral lesions. Oral lesions detected most frequently included OHL 
(9.9%), HIV associated periodontal diseases (9.9%) and OC (4.9%). 
Three patients (1.5%) had multiple papillomatous growths. This 
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study showed a low prevalence of HIV associated oral lesions and a 
change in the pattern of predominant lesions in the era of HAART. 
These lesions were more likely to be found in patients with 
advanced disease, patients not receiving therapy, or in patients in 
whom therapy was failing. 
 
Reznik D (2005)49  reviewed the HIV related oral conditions in HIV 
infected individuals. Common oral lesions in HIV patients included 
xerostomia, OC, OHL, periodontal disease, KS, HPV associated 
warts and oral ulcers. It was noted that the prevalence of oral 
lesions reduced from 47.6 to 37.5% after introduction of HAART.  
 
Flint S R, Tappuni A, Leigh J et al  (2006)50  reviewed the literature 
on oral lesions in HIV patients and reported that the overall 
prevalence of HIV related oral disease decreases with HAART 
therapy. Lesions such as oral warts and salivary gland disease 
decreased with the use of HAART.   
 
Tappuni A and Fleming G (2001)  5 1  compared the prevalence of 
oral lesions among 89 HIV infected patients who were on ART and 
195 HIV infected patients not on ART. The prevalence of oral 
lesions was 30% in patients on any ART compared with 46% in 
patients not on ART. 
 
Sharma G, Pai KM, Suhas S et al  (2006)4 5  evaluated the 
prevalence of oral lesions in HIV positive individuals. Oral 
manifestations were seen in 79% of patients.  EC (44.5%) was the 
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most common lesion, followed by melanotic hyper pigmentation 
(34.6%), OHL (15.8%), linear gingival erythema (15.8%), PC 
(11.8%) and angular cheilitis  (11.8%). 
 
Umadevi K, Ranganathan K, Pavithra S et al  (2007)15  described 
oral lesions in hundred HIV positive patients initiated on highly 
active anti-retroviral therapy (HAART). A significant decrease in 
the occurrence of OC (from 24% to 8%) was seen in patients after 
initiation of HAART. The prevalence of oral melanin pigmentation 
in patients with CD4+ cell counts of >200 cells/µl increased from 
14.8% to 43.8% after initiation of HAART. 
 
Greenspan D, Canchola J, MacPhail L et al  (2001)1 3  investigated 
the change in prevalence of oral lesions after initiation of HAART 
in HIV patients. This retrospective study revealed a significant 
decrease in common oral lesions and increase in salivary gland 
disease.  The prevalence of oral warts was 5% among patients not on 
any anti-retroviral medication, whereas it  was 15% in patients on 
anti-retroviral therapy and 23% in patients on HAART.  
 
King M, Reznik D, O’Daniels C M et al  (2002)12  conducted a case-
control study to assess the oral warts among HIV sero-positive 
patients.  The prevalence of oral warts among 2194 HIV seropositive 
patients was 2.6%. The HIV viral load was lower among patients 
with oral warts. An association between the use of HAART and oral 
warts was not seen.  
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Cameron J, Marcante D, O’brien M et al  (2005)1 1  assessed the 
impact of highly active anti-retroviral therapy (HAART) on oral 
HPV prevalence. Prevalence of HPV was 35 % in the saliva of HIV 
positive patients. High-risk HPV types were more prevalent (26%) 
than low-risk types (4%). HPV16 was the most prevalent genotype 
followed by HPV-55 and 83. An increase in oral HPV was noted 
with increasingly effective HAART. 
 
Shetty K and Leigh (2006)5 2  described case reports of 4 HIV 
positive patients who presented with multiple raised papillary 
lesions on the labial mucosa. These cases suggested a predilection 
for the labial mucosa for occurrence of oral warts in the HIV 
positive patients on HAART. 
 
Fakhry C, D’Souza G, Sugar E et al  (2007)3 7 evaluated the 
presence of oral HPV in the oral rinse and cervical vaginal lavage 
specimens of 123 HIV positive and 59 HIV negative women. These 
patients were re-examined and samples were again collected after  
six months and assessed. In HIV-positive women HPV DNA was 
detected in 24% and 23% of the oral rinse samples and 75% and 
70% of cervical vaginal lavage specimens during baseline and 
follow up examination. This was very much high when compared 
with oral (8.5% and 13.6%) and cervical (42% and 41%) HPV DNA 
prevalence among HIV–negative women. The six month cumulative 
prevalence of oral HPV infection (33%) was significantly less than 
that of cervical infection (78%). At follow-up, among HIV-positive 
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women, the rate of oral HPV infections newly detected was 
significantly lower than cervical infection (p<0.001). 
 
Samples used for HPV detection 
Zhao M, Rosenbaum E, Koch Wet al  (2005)53   to determine the 
feasibility of using  saliva rinses as a screening tool for patients  
with head and neck cancer in a normal population, the authors 
studied the presence  of HPV 16  in saliva rinse from patients with 
head and neck squamous cell carcinoma (HNSC) and normal control 
subjects.  Real time quantitative PCR was used to detect HPV 19 
DNA in 93 primary tumours and salivary rinses of these patients and 
604 control subjects without HNSC. 45.6% of primary HNSC and 
32.6% of saliva rinse samples from HNSC patients had HPV 
whereas only 2.8% of the controls had HPV16 in saliva rinses. 
Based on these they concluded that salivary rinses have a potential 
for use in molecular screening for HPV-related HNSC. 
 
Furrer V E, Benitez M B, Furnes M et al  (2006)54  evaluated the 
use of a non-invasive technique for HPV genotyping. They 
compared biopsies and superficial scrapes as sampling methods for 
the detection of HPV DNA and determination of the HPV genotype 
spectrum in potentially malignant and malignant oral lesions once 
clinical features of the lesions were determined. Of the 22 patients  
with potentially malignant and malignant lesions, 41% of the 
biopsies were HPV DNA positive, whereas 95–100% of the 
superficial scrapes were positive. Based on these findings they put 
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forth that the information on oral HPV infection/oral carcinogenesis 
depends not only on the DNA detection technique, but also on the 
tissue/cell sampling procedure. 
 
Methods of Human Papilloma Virus detection 
Elamin F, Steingrimsdottir H, Wanakulsuriya S et al  (1998)2 4  
evaluated the role of HPV in oral neoplasms using nested PCR. 
They analysed oral biopsies collected from 40 patients who were 
clinically diagnosed as SCCs or potentially malignant mucosal 
lesions Amplification product was not detected by ethidium bromide 
staining after the first stage of PCR using MY11/09 primers,  
whereas, 22 of the 40 samples yielded a detectable PCR product 
when tagged with radioactive phosphorus (2 2P) and separated on an 
8% polyacrylamide gel after the second stage of PCR. HPV 16 and 
HPV 18 were the only types detected in all  tumors by HPV typing.  
 
Karlsen F, Kalantari M, Jenkins A et al  (1996)5 5  studied HPV 
detection in a large series of patients with cervical carcinoma using 
multiple PCR primers from E1, E6-E7 and L1 lesions of HPV 
genome. Type-specific primers for HPV 16, 18, 31, 33 and 35 
detected more HPV infected patients than the most sensitive 
consensus primer set,  whereas the three consensus primer sets MY 
09-11 Gp 5+ - 6+ and CpI-CpIIG, together detected more HPV 
positive patients than type-specific primers. This suggests that in 
PCR detection systems, multiple consensus primers and type-
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specific primers should be used in order to detect all  patients 
harbouring HPV. 
 
Harnish D, Belland M, Scheid E et al  (1999)5 6  compared the five 
commonly employed PCR consensus primers employed for detection 
and typing of HPV. Yoshikawa, Manos, Gregoire, van den Brule and 
Snijders primers (derived from the consensus sequences of L1 or E1 
open reading frames) when used to detect HPV DNA in standard 
HPV DNA-containing preparations, exhibited approximately equal 
sensitivity.  
 
Castle P, Schiffman M, Gravit P et al  (2002)57  analysed 2978 
cervical cell  specimens by MY09–MY011primer set,  using Ampli  
Taq Gold DNA polymerase (MY-Gold) and compared with 
AmpliTaq DNA polymerase (MY-Taq). They then redesigned a new 
MY09/11 primer set (PGMY-Gold), and compared with MY-Gold 
for HPV DNA detection. A good agreement between the two 
methods and no significant differences in HPV detection was seen. 
It was found that MY-Gold was a more sensitive assay for the 
detection of HPV DNA than MY-Taq. They suggested that studies 
reporting HPV DNA detection by PCR need to report the type of 
polymerase used, as well as other assay specifications. 
 
Malijn A, Kleter B, Quint W et al  (2004)5 8  reviewed the molecular 
diagnostic methods used to detect and identify HPV. The methods 
for HPV nucleic acid detection  methods include, signal 
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amplification system, target amplification systems (including type 
specific and broad spectrum PCR, real time PCR and RT-PCR) and 
detection and analysis of amplified products (PCR and restriction 
fragment length polymorphism, hybridization analysis of PCR 
products, microtiter plate hybridization, direct sequence analysis of 
PCR products and reverse hybridisation). 
 
D’Souza G, Sugar E, Ruby W et al  (2005)59   investigated the effect 
of proteinase K digestion (PKD) and heat inactivation; PKD and 
ethanol precipitation (EP); PKD, phenol-chloroform extraction, and 
EP; use of the Puregene DNA purification kit;  and use of the 
QIAamp DNA Blood Midi kit  for DNA purification..  Puregene-
purified samples had higher human DNA yields and Puregene 
purification detected the greatest number of HPV-positive subjects  
and total HPV infections in comparison to the numbers detected by 
all  other methods. They concluded that the method of DNA 
purification from oral rinse samples has a potentially large impact 
upon the ability to detect HPV genomic DNA in these samples by 
PCR amplification. 
 
Boy S, Van Rensburg E, Engelbrecht S et al  (2006)60  compared 
the three types of nucleic acid hybridization methods for HPV 
detection, namely Southern blot,  In-situ hybridization (ISH) and 
hybridization signal amplification to evaluate the prevalence and 
possible role of HPV in primary OSCC in a South African 
population. Of the 59 OSCC cases analysed, HPV18 DNA was 
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detected in the primary tumours of seven patients using real-time 
PCR, whereas no HPV signals were detected with ISH or amplified 
ISH techniques. They concluded that HPV is probably unimportant 
in pathogenesis of OSCC and hypothesize HPV detection techniques 
as the main reason for the positive results in many studies. 
 
Castle P, Porras C, Quint W et al  (2008)61 compared two 
consensus primer PCR genotyping methods one based on the PGMY 
primers and one based on the SPF10 primers for the detection of 
individual HPV genotypes and carcinogenic HPV genotypes as a 
group in the cervical specimen of females. These methods differed 
in the following ways: DNA extraction and purification, amount of 
purified DNA amplified, PCR primers used and the method of 
amplicon detection. They found that both the methods were very 
similar in the overall detection of carcinogenic HPV but the linear 
array method detected more HPV16, 18, 39, 58, 59, 66, and 
HPV68/73, while the SPF10 method detected more HPV11, 31, and 
HPV52. 
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10 HIV seropositive patients who were on HAART for six 
months duration constituted the study Group I.  Ten HIV 
seronegative individuals were included in the study, as control 
group (Group II).  Group I (Table 1, Graph 1)  comprised of 8 (80%) 
males and 2 (20%) females. The mean age of the patients in group I 
was 35 ± 8.95years. Of the 10 Group I patients,  there were 4 (40%) 
patients in 21-30 years age group, 3 (30%) patients in 31-40 years 
age group and 3(30%) patients in 41-50 years age group. (Table 2, 
Graph 3)  
 
Group II comprised of 4 (40%) females and 6 (60%) males 
(Table 1, Graph 2). The mean age of the subjects in the group II /  
control group was 27.6± 6.17 years. Of the 10 Group II patients,  
there were 7 (70%) patients in 21-30 years age group, 2 (20%) 
patients in 31-40 years age group and 1(10%) patients in 41-50 
years age group (Table 2, Graph 3)  
 
The systemic lesions among the patients in group I (n=10) 
were tuberculosis (n=3), haemophillia (n=1) and hydrocele (n=1), 
lypodystrophy (n=1), diabetes (n=1). 
 
On intraoral examination, of the 10 patients in group I,  5 
(50%) presented with gingivitis or periodontitis,  2 (20%) presented 
with OC, 2 (20%) presented with increased oral melanin 
pigmentation, 2 (20%) presented with oral submucous fibrosis and 2 
(20%) presented dental caries.  
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The predominant route of transmission of HIV in group II 
subjects was heterosexual transmission (n=8, 80%), one patient 
acquired the infection through homosexual route and another patient 
through blood transfusion (Table 3, Graph 4)  
  
 The drug regimen taken by group I subjects was 
2NRTI+1NNRTI (N=9, 90%), 1NRTI+PI (N=1, 10%) (Table: 4, 
Graph: 5)  
 
The mean CD4 count of group I subjects prior to the initiation 
of HAART was 122±73.9cells/cu mm and after six months of 
initiation of HAART was 311±104.4cells/cu mm, (P=0.000) (Table 
5, Graph 6)  
 
The mean hemoglobin count of group I subjects prior to the 
initiation of HAART was 11.97±2.38gm/dl and after six months of 
initiation of HAART was 13.8±1.46gm/dl, (P=0.024) (Table 6, 
Graph 7)  
 
Saliva samples were collected from all the 10 patients in 
group I.  Scrapings from buccal mucosal were obtained from 5 of the 
10 patients in group I,  chosen randomly. Saliva samples were 
collected from all the 10 patients in group II.  DNA was extracted 
from all  the samples as per the protocol.   
 
All the samples, along with positive and negative controls 
were amplified using housekeeping gene and MY09/11 primers to 
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amplify β-globin and L1 regions in a multiplex PCR. Amplified 
products were subjected to gel electrophoresis. In each gel the 
positive control DNA from HeLa cell line and negative control 
without any DNA were included. 
 
The DNA ladder marker was added, in the first or second 
wells of each gel,  with which the molecular weight was compared. 
 
In each gel,  the PCR amplification products of all the samples 
and positive controls showed a clear band for housekeeping gene, β-
globin at 250 base pairs (at a level between the marking 200 and 
300 on 100 base pairs ladder). 
 
HPV was not detected in any of the samples in both groups 
(Figure: 8, 9, 10, 11) .  No band was seen corresponding to 450 base 
pairs size (at a level between the marking 400 and 500 on 100 base 
pairs ladder) in samples from both groups as well as negative 
control,  though positive control yielded a clear band at 450 base 
pairs.  
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Oral lesions in HIV infection are the earliest and one of the 
most important indicators of HIV infection. These lesions may be 
present in upto 50% of patients with HIV infection and in upto 80% 
of those with a diagnosis of AIDS. These lesions parallel the 
decline in CD4+ cell counts and an increase in viral load. They are 
important indicators of disease progression and immunosuppression. 
Their importance has been demonstrated and emphasized by many 
researchers2  
 
Mortality and morbidity related to AIDS have decreased 
among HIV infected patients taking highly active antiretroviral 
therapy (HAART)5  .  A marked reduction in the prevalence of many 
oral lesions have been reported after the introduction of HAART. 
 
 HPV infection has taken on much greater significance in 
recent years, as the frequency of HPV  infection has increased in 
examined groups following the introduction of HAART and  
especially, given the fact that  this virus may be involved in the 
etiology of squamous cell carcinoma8. 
 
 Greenspan et al  (2001) among the 1280 patients referred to 
their clinic  in San Fransisco over a period of 9 years, reported an 
increase in the prevalence of oral warts in patients on anti- 
retroviral therapy (15%) and patients on  HAART (23%) when 
compared to patients not on any anti-retroviral medication (5%)13.  
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LL Patton et al  (2000) reported that though the prevalence of 
oral lesions (hairy leukoplakia, necrotizing periodontal disease) 
significantly decreased, there was a significant increase in the HIV 
associated salivary gland disease and human papilloma virus 
infections. 62  
 
Green wood et al (2002), in their retrospective study of 1590 
patients attending the dental clinic at UK, found that there was a 
marginal increase in the incidence of HPV lesions following 
HAART with significant decline of other oral lesions. Andrea M et 
al  in their study of a German cohort of 103 HIV positive patients  
also reported a similar findings.63 Mark D king et al in their study 
of 2194 HIV positive patients attending the health centre at Atlanta,  
Georgia also reported that the prevalence of oral HPV increased 
significantly in the era of HAART, the prevalence and incidence of 
HPV was 2.6 and 1.6 respectively. 64  
 
The cause of high prevalence of oral HPV infection in HIV 
infected individuals is not clear.  The high risk sexual practices that 
are common among HIV infected individuals and multiple exposures 
may predispose HIV infected individuals to acquire HPV. 
Alternatively, the higher HPV detection rates could be due to 
increased HPV replication and/or persistence rather than increased 
HPV acquisition.15  
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Langerhans cells, which are important for antigen 
presentation, have been shown to be depleted in the oral mucosa of 
HIV infected persons. It  has also been hypothesized that restoration 
of langerhan cells and CD4 T lymphocytes occurring in the oral 
mucosa in response to reduction in viral load allow for a marked 
improvement for HPV antigen recognition and presentation. 
Subsequently, local inflammatory responses may also improve, 
when the inflammatory response become marked, clinically evident 
oral warts become marked6 5. 
 
HIV regulation of HPV transcription is another possible 
mechanism for the increase risk of oral warts seen in response to 
significant reduction of viral load. The presence of HIV tat proteins 
has been found in condyloma accuminatum tissue samples obtained 
from HIV infected patients for biopsy66  
 
It  is also postulated that individuals who are on HAART have 
already been immunocompromised long enough to surpass some 
critical threshold for developing HPV related disease, which may 
not be reversed with antiretroviral therapy.11  
 
Other reasons for the reported increase in incidence of oral  
warts could be epidemiological,  chemical (direct impact of 
treatment regimens on the host/virus),  viral (interactions between 
the HIV and HPV) and immunological (lack of restoration of an 
essential component of HPV immune control)67  
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It is  known that clinical lesions are not manifested in all  
cases of oral HPV infection and diagnosis of sub-clinical infections 
is easily missed.  Hence we used a molecular method (PCR) to detect 
HPV in our study. Majority of the previous studies in HIV infected 
patients have focussed on detection of oncogenic HPV-16 and HPV-
18 subtypes in the head and neck region, with few reports on other 
oncogenic and low risk types of HPVs3 5 , 3 6 ,37 .  
 
We used a consensus L1primer set  (MY 09/11) since it  
amplifies the L1 region of HPV genome which is highly conserved.  
 
HPV has been detected in the saliva and buccal mucosal 
scrapings previously by Cameron et al  (2005)1 1.    They studied the 
saliva of 98 HIV positive individuals and detected HPV infection 
more frequently in patients on effective HAART (57%) compared to 
those on clinically ineffective HAART (29%). HAART efficacy was 
defined by a HIV viral load <400 copies/ml in their study.  Oral 
HPV was detected in 37% of HIV positive African American 
individuals.  Caucasians were at greater risk of oral HPV infection 
than African Americans11. 
 
 Zhao et al5 3 and Karlsen et al  (1996)5 5 have done similar 
studies by using MY 09/11 primers and successfully detected the 
HPV DNA. Both high and low risk HPV types have been detected 
using L1 consensus primer. 
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In our study we used RBC spin column based DNA extraction 
kit  to extract DNA from the samples. Both unstimulated saliva and 
scrapings from buccal mucosa were analysed. All the samples had 
more than 50ng/µl of DNA. For PCR analysis,  5-10ng of DNA is 
sufficient.  The DNA so obtained was subjected to the PCR 
amplification and gel electrophoresis, to amplify the housekeeping 
gene and HPV DNA. All the samples were positive for housekeeping 
gene, confirming the presence of adequate amounts of DNA for PCR 
analysis.  None of the samples showed HPV positivity, though all  the 
positive controls gave a positive test result.  This confirmed that the 
PCR did not have any inhibitors and the amplification and detection 
of amplified products was defective.  
 
In our study we did not find any HPV genome positivity 
following HAART therapy, a finding contrary to that of Cameron et 
al1 1  as they identified HPV genome in those on HAART and not on 
HAART. In HIV patients on HAART, it  was detected more 
frequently in patients on clinically effective HAART (57%) or 
marginally effective therapy (54%) compared to those on clinically 
ineffective HAART (29%). A geographically varied group of 
Africans, Americans and Caucasians were enrolled in this study. 
 
Oral mucosal abnormalities and more than one oral sex 
partner and oral sex with men are known to be associated with HPV 
seropositivity13.  In our study the patients were predominantly  
heterosexual (80%) in behaviour with the possibility of reduced 
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frequency of oro-genital contacts and this could possibly explain the 
absence of oral warts in our study, whereas in the study by Cameron 
et al ,  only 14 % of the patients were heterosexual.  
 
The increased risk of oral warts that accompanies reductions 
in viral load following HAART may represent a form of immune 
reconstitution syndrome occurring in response to improved cell 
mediated immune function6 4.  It  is possible that reconstitution of the 
immune system may be functionally incomplete and its effectiveness 
might therefore vary with regard to different pathogenic 
microorganisms. In particular newly generated CD4 cells are sub 
optimally immunocompetent,  hence permitting replication of HPV 
and development of oral lesions9. 
 
Our study was a longitudinal study. The mean follow up 
duration was ±10.6 months. In our study patients there was a 
significant rise in the CD4 count suggestive of effective HAART 
therapy.  In the study by Greenspan et al,  increased HPV induced 
wart in the post HAART era was suggested as a feature of immune 
reconstitutional inflammatory syndrome (IRIS).  IRIS manifests in 
about 6 months of the initiation of HAART and none of our patients  
clinically or sub clinically possessed any HPV genome1 3.   
 
In this study we used L1 consensus primer that amplifies the 
450 base pair,  and this was considered to be the most sensitive 
method for detection of HPV. Given the fact that we could not 
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detect HPV in our patients who were on HAART, we state that there 
is absence of HPV in the oral cavity of our cohort.  
 
Oral warts occurring in HIV seropositive patients often have 
an uncharacteristic morphology and may be recalcitrant to therapy 
and HPV related lesion in HIV disease may be associated with 
moderate or severe oral epithelial dysplasia9.  
 
Given these facts we state that there is a need to adopt a 
screening procedure to determine the likely risk of oral carriage of 
HPV in order to ensure careful clinical follow up of these patients  
who are especially on HAART. 
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• This study was done to detect HPV in the saliva of HIV 
seropositive patients on HAART therapy (for ateast six 
months)  
• Ten HIV seropositive patients were recruited  for the study≥  
six months of  initiation of HAART (group I)  and 10 HIV 
seronegative subjects were controls (Group II) 
• DNA was extracted from all the salivary samples. The DNA 
was quantified (≥25 µg/dl) 
• Extracted DNA was amplified for the identification of HPV 
using L1 consensus primers and primers to amplify the house 
keeping gene by multiplex PCR method 
• All samples were positive for β  globin (house keeping) gene 
and positive control (infected HeLa cell line DNA) was 
positive for HPV DNA 
• We were unable to detect HPV DNA in our study subjects of 
both group 
 
We used the most sensitive method, PCR  to detect HPV 
genome  in our study subjects.  To understand the biology of HPV 
infection in HIV seropositive patients,  more longitudinal studies are 
necessary especially in the context of HAART. 
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ANNEXURE 1: Demographic details, clinical history, drug regimen and laboratory findings of study group – group I (HIV seropositive patients on ≥ 6 months of HAART)
O.P NO HAART 
INITIATION
DRUG 
REGIMEN
CD4 
COUNT
CD4 
(POSTHA
ART)
Hb Hb (post 
HAART)
REGIMEN DURATION 
OF HAART
AGE SEX OCCUPATION MARITAL 
STATUS
MODE OF 
TRANSMISION
SYSTEMIC 
LESION PRE 
HAART
SYSTEMIC 
LESION POST 
HAART
ORAL LESION 
PRE HAART
ORAL LESION 
POST HAART
HPV detection
M471 13.11.09 EFV+3TC+TDF 175 461 14.8 13.4 2NRT+1N
NRTI
6 23 m STUDENT SINGLE BLOOD 
TRANSFUSION
HAEMOPHILLIA HAEMOPHILLIA GINGIVITIS GINGIVITIS NEGATIVE
L260 19.11.09 AZT +3TC +EFV 166 236 10 10.9 2NRT+1N
NRTI
7 50 f HOUSE WIFE WIDOW HETEROSEXUA
L
NIL NIL MELANOSIS MELANOSIS NEGATIVE
A813 19.08.09 ATV+RTV+EFV 163 356 13.8 13.6 1NRT+2PI 10 43 m COOL DRINKS 
SHOP
MARRIED HETEROSEXUA
L
TUBERCULOSIS TUBERCULOSIS GINGIVITIS GINGIVITIS NEGATIVE
S3173 17.9.09 TDF + 3TC+EFV 29 304 9.2 13.6 2NRT+1N
NRTI
10 40 m FINANCE 
BUSSINESS
MARRIED HETEROSEXUA
L
TUBERCULOSIS TUBERCULOSIS PERIODONTITI
S,ROOTSTUMP
PERIODONTITI
S,ROOTSTUMP
NEGATIVE
S3220 12.08.09 EFV+3TC+TDF 50 419 14.9 15.9 2NRT+1N
NRTI
14 34 m AGRICULTURE SINGLE HETEROSEXUA
L
TUBERCULOSIS TUBERCULOSIS PC,GINGIVITIS GINGIVITIS NEGATIVE
S3106 01.10.09 AZT +D4T +EFV 95 308 11.3 14.9 2NRT+1N
NRTI
8 23 m LABOURER SINGLE HOMOSEXUAL NIL NIL OSMF,PC OSMF NEGATIVE
Y75 11.11.09 EFV+3TC+D4T 226 382 12.1 13 2NRT+1N
NRTI
10 38 f LABOURER MARRIED HETEROSEXUA
L
NIL UTI GINGIVITIS GINGIVITIS NEGATIVE
S3161 1.10.09 EFV+3TC+D4T 56 148 9.2 14.9 2NRT+1N
NRTI
8 28 m DRIVER SINGLE HETEROSEXUA
L
HYDROCELE NIL DENTAL 
CARIES
DENTAL 
CARIES
NEGATIVE
K983 26.09.09 AZT+3TC+NVP 211 341 9.8 13.2 2NRTI+1N
NRTI
13 41 m AGRICULTURE MARRIED HETEROSEXUA
L
DIABETIC DIABETIC,LYPH
O DYSTROPHY
PC,MELANOSIS PC,MELANOSIS NEGATIVE
S3211 13.09.09 TDF+3TC+EFV 50 157 14.6 15.5 2NRT+1N
NRTI
12 30 m SHOP KEEPER MARRIED HETEROSEXUA
L
PCP COUGH, 
BREATHLESSNE
SS
OSMF OSMF NEGATIVE
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ANNEXURE 2 
Oral HPV Types and Diseases 
Genotype Diseases 
HPV 2, 4 Verruca Vulgaris 
HPV 6, 11  Condyloma Acuminatum, Squamous Papilloma 
HPV 13, 32  Focal Epithelial Hyperplasia 
HPV 16 Proliferative Verrucous Leukoplakia 
HPV 6, 11, 16 Verrucous Carcinoma 
HPV 16, 18 Squamous Cell Carcinoma 
  
